

Cell Based Therapy: An Insight into Voyage of New Generation Therapeutics



Lokendra Singh Rathor @, Ankita Wal #, Manju Rawat Singh @*

@ University institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur CG

Institute of Pharmacy, Praveer Singh Institute of technology, Kanpur, UP

manjursu@gmail.com

Introduction

Cell therapy is the technique involving transfer of cells from the patient (autologous) or from a donor (allogenic) into a patient with the goal of improving a disease (1,2). The first cell treatment procedures were performed in 1889 by Charles Edouard Brown-Sequard, who was considered a pioneer in hormone therapy. He used injections of animal testicle extracts to slow down the effects of ageing (3). Cell therapy is currently evolving due to continued research on its clinical safety and efficacy. There has been constant surge of interest on cell therapy evident with the size of global market expected to 9.5 USD billion in 2021 to 23 USD billion by 2028. [4] Cell based therapy includes unicellular or multicellular therapies based on stem cells and non-stem cells. Cell therapy is widely used in various therapeutic fields, comprising cancer treatment, immunotherapy, and regenerative medicines.

Cell-based therapies have come up as a boom due to its marked potential to prevent a wide range of disorders that are presently incurable due to their remarkably effective mechanism of action. Despite major recent clinical and financial accomplishments, cell-based medicines still need to be translated and commercialised widely before they may be used in routine. These obstacles include choosing the right cell source, developing a product that is sufficiently valuable, effective, and non-toxic and meets the needs of particular patients and diseases, and creating scalable manufacturing methods. The research supported by next-generation engineering techniques, such as genome and epigenome editing, synthetic biology, and the utilisation of biomaterials, is being used to overcome these obstacles.

Treatment of multiple disorders with stem cell therapies

The initial description of "stem cells" started in 1888 marked the beginning of a significant development in the field of rejuvenation drugs. In 1902, the first recognition of hematopoietic stem cells was identified. In 1939, the first bone marrow transplant was carried out to treat aplasmic anaemia. In the intervening period, the growth of stem cell-based therapy has seen numerous breakthroughs and significant achievements made in respect to the conversion of fundamental research into pre-symptomatic investigations and clinical diagnosis. Human

pluripotent stem cells were later discovered, and their isolation in 1991 was followed by the development of stem cell-based treatment for the treatment of human diseases (Fig 1a).

Cell origins of stem cell-based treatment- undifferentiated cells such as foetal stem cells (originate from the blastocyst, an inner mass cell) and developed embryonic stem cells, give rise to a variety of human cell types, including the three germ layers, and can multiply indefinitely in vitro. Multipotent stem cells originating from mesoderm, mesenchymal stem cells have the capability to remodel itself (restricted in vitro) and have the capacity to diverge into mesenchymal lineages. Induced pluripotent stem cells are developed by reprogramming differentiated cells to return to the pluripotent stage using OSKM factors. It is crucial to remember that as compared to differentiated/somatic cells, stem cells exhibit a significant greater risk of tumour development with lesser threat of graft rejection (Fig 1b).




Figure 1(a) The source history of cell




Figure 1 (b) diagrammatic representation of various cell sources that used in stem cell-based treatment

Immune system stem cell therapy

The majority of immunological system illnesses are brought on by autoimmune disorder or overactive immune responses. Therefore, the main goals of treatment are to reduce infection cause, effects, and it's recurrent nature. The goal of using cell therapy for immune system illnesses is immune system resetting as a permanent treatment, not just immune suppression and symptomatic relief (5). HSCT/BMT emerged as the most popular cell-based remedy for the treatment of immune system illnesses from 1990s (6). It has been shown that severe SS can benefit from HSCT with manageable ratio of transplant-linked death (7). In controlled phase two-third studies, hematopoietic stem cell transplantation (HSCT) has shown to be effective in treating patients with autoimmune disorders. For instance, patients with multiple sclerosis experienced 78-80% advancement in their disability status and notable improvements in the disease re-occurrence rates, MRI abrasions, and quality well beings (8). The patients with systemic lupus erythematosus (SLE), hematopoietic stem cell transplantation (HSCT) and peripheral blood stem cells (PBSCT) also reduced disorder activity and improved organ failure. Platelet rich protein (PRP) demonstrated to reduce swelling, pruritis and eruption of inflamed cell by using ultrasound source imaging remarks in patients with RA (9), and regulatory T cell, which are shown to lower the prevalence of acute Graft versus host disease (GVHD), or other stem cell-based treatment besides few frequently reported benefits in immunological disorders.

Cancer stem cell therapy

The goal of melanoma therapy has changed from systemic tumour to target using chemotherapy and radiation therapy to a new focused strategy utilising new biological therapies, such as (APC)-based anticancer vaccines, oncogenic infections, and cell-line therapy, such as monoclonal antibodies and CAR-T cells (10). Numerous cell treatments have been researched for the treatment of cancer in clinical settings in addition to commercial cell therapy products. Only primary CD1c+ myeloid DCs can be used to make DC-based anticancer vaccines, or patient-derived tumour cells and tumour peptide can be combined to make them. Dendritic cell-based antineoplastic vaccines can be generated using only key CD1c+ myeloid dendritic cell s or can be created via fusing patient-derived tumour cells with tumour peptide (11).

Multicellular versus Unicellular Stem cells

Starting from the base first the unicellular stem is being used but recently it has moved towards the multicellular stem cell-based therapy. Anticoagulated blood, or platelet-rich plasma (PRP) product made by differentially centrifuging the total blood, is mostly composed of platelets in amounts that can be up to five times higher than normal platelet concentrations (12). Megakaryocytes mature to produce platelets, which are acellular fragments that primarily serve to maintain primary haemostasis and thrombosis in order to maintain vascular integrity (13). PRP comprises cellular components, such as leukocytes, despite being predominately composed of platelets, which are repositories of numerous immunologic compounds, soluble proteins, and growth factors (14). PRP can be processed using a variety of commercially available kits, with different results according to the concentrations of leukocytes, platelets, and red blood cells. Composition of PRP can be examined using a variety of analytical techniques, including microscopy, flow cytometry, and spectrophotometry (15).

PRP products can be heterogeneously formulated due to their unstandardized preparation processes. Several non-consensual classification methods, such as the International Society on Thrombosis and Hemostasis, the PLRA, and the PAW systems, are used to further categorise substances cellularity, platelet concentrations, and activation further taken into account in clinical situations (16). PRP works by a variety of mechanisms that are fueled by nucleated cells, cytokines, platelets and growth factors, which all work together to reduce inflammation and encourage tissue repair (17).

An organism's multicellularity enables cell-cell interaction, which is necessary for many stages in the process of tissue formation that begins early in embryogenesis and continues through subsequent regeneration processes. Multiple cell types, as opposed to just one, are required to enable long-term tissue regeneration, which is fuelled by multifaceted, well understood multicellular interactions typical of organisms' physiological functions, according to a growing body of evidence in regenerative medicine (18). Similar to this, a recent retrospective review of patients who had medial unicompartmental knee OA treatment with high tibial osteotomy with microfracture and either MSCs or BMAC discovered no differences in pain/functionality radiological findings and outcomes postoperative (19). Additionally, multicellular therapies may be more successful than biologic treatments comprised of a single cell type for cancer treatment. When assessed to patient-derived CIK cells, combinations of in vitro tests with DCs and CIK cells have revealed better antineoplastic activity.

Conclusion

Cell therapy is a growing industry that incorporates stem cell and the non-stem cell-based unicellular and multicellular treatments. These treatments range significantly in terms of their properties, sources of isolation, and applications. However, a number of obstacles still need to be overcome for clinical use of cell treatments for conditions like neurodegeneration illnesses in which the Clinical outcomes are difficult to evaluate due to the standardisation of cell mechanised techniques and the delayed disorder onset. Other impediments to cell development therapies are linked to safety, which with some products like CAR-T cells may present toxicities that, are fatal. Other benefits of multicellular therapies over unicellular therapies include their reduced cost and increased potential for use as a bridge to precision medicine by the rapidly developing fields of gene engineering and bioinformatics.

Abbreviations: BMT/HSCT-(bone marrow transplant/hematopoietic stem cell transplant), PBSCT(peripheral blood stem cells) CAR-T(chimeric antigen receptor cell), DC (dendritic cell), MSC (mesenchymal stem cell), CIK(cytokine induced killer), PRP(platelet rich protein)

References

1. Kim I. A brief overview of cell therapy and its product. *J Korean Assoc Oral Maxillofac Surg.* (2013) 39:201. doi: 10.5125/jkaoms.2013.39.5.201.
2. American Society of Gene and Cell Therapy. *Gene & Cell Therapy FAQs.* (2021). Available online at: <https://asgct.org/education/more-resources/gene-and-cell-therapy-faqs> (accessed April 24, 2021).
3. Lefrère JJ, Berche P. La thérapeutique du docteur Brown-Séguard. *Ann Endocrinol.* (2010) 71:69–75. doi: 10.1016/j.ando.2010.01.003
4. *Cell Therapy Market Size Analysis Report, 2021–2028* by Grand View Research SF, California (2021).
5. Dazzi F, Van Laar JM, Cope A, Tyndall A. Cell therapy for autoimmune diseases. *Arthritis Res Ther.* (2007) 9:206. doi: 10.1186/ar2128
6. Aly RM. Current state of stem cell-based therapies: an overview. *Stem Cell Investig.* (2020) 7:8. doi: 10.21037/sci-2020-001
7. Farge D, Passweg J, Van Laar JM, Marjanovic Z, Besenthal C, Finke J, et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR registry. *Ann Rheum Dis.* (2004) 63:974–81. doi: 10.1136/ard.2003.011205
8. Ramalingam S, Shah A. Stem cell therapy as a treatment for autoimmune disease—updates in lupus, scleroderma, and multiple sclerosis. *Curr Allergy Asthma Rep.* (2021) 21:22. doi: 10.1007/s11882-021-00996-y

9. Badsha H, Harifi G, Murrell WD. Platelet rich plasma for treatment of rheumatoid arthritis: case series and review of literature. *Case Rep Rheumatol.* (2020) 2020:1–7. doi: 10.1155/2020/8761485
10. Schirrmacher V. From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment. *Int J Oncol.* (2019) 54:407–19. doi: 10.3892/ijo.2018.4661
11. Anguille S, Van De Velde AL, Smits EL, Van Tendeloo VF, Juliusson G, Cools N, et al. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. *Blood.* (2017) 130:1713–21. doi: 10.1182/blood-2017-04-780155
12. Pavlovic V, Ciric M, Jovanovic V, Stojanovic P. Platelet rich plasma: a short overview of certain bioactive components. *Open Med.* (2016) 11:242–7. doi: 10.1515/med-2016-0048
13. Kojok K, El-Kadiry AE-H, Merhi Y. Role of NF- κ B in platelet function. *Int J Mol Sci.* (2019) 20:4185. doi: 10.3390/ijms20174185
14. El-Kadiry AE-H, Merhi Y. The role of the proteasome in platelet function. *Int J Mol Sci.* (2021) 22:3999. doi: 10.3390/ijms22083999
15. Fitzpatrick J, Bulsara MK, McCrory PR, Richardson MD, Zheng MH. Analysis of platelet-rich plasma extraction: variations in platelet and blood components between 4 common commercial kits. *Orthop J Sport Med.* (2017) 5:1–8. doi: 10.1177/2325967116675272
16. Everts P, Onishi K, Jayaram P, Lana JF, Mautner K. Platelet-rich plasma: new performance understandings and therapeutic considerations in 2020. *Int J Mol Sci.* (2020) 21:1–36. doi: 10.20944/preprints202010.0069.v1
17. US FDA. Statement on stem cell clinic permanent injunction and FDA’s ongoing efforts to protect patients from risks of unapproved products. FDA Statement. (2019). Available online at: <https://www.fda.gov/news-events/press-announcements/statement-stem-cell-clinic-permanent-injunctionand-fdas-ongoing-efforts-protect-patients-risks> (accessed July 24, 2021)
18. Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, Zhou J, et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. *J Immunol.* (2004) 173:7125–30. doi: 10.4049/jimmunol.173.12.7125
19. Lee N-H, Na S-M, Ahn H-W, Kang J-K, Seon J-K, Song E-K. Allogenic human umbilical cord blood-derived mesenchymal stem cells is more effective than bone marrow aspiration concentrate for cartilage regeneration after high tibial osteotomy in medial unicompartmental osteoarthritis of knee. *Arthroscopy.* (2021) 37:2521–30. doi: 10.1016/j.arthro.2021.02.022